BRBoris Reva

Boris Reva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boris Reva has a total of 315 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Abstract 70: Metastatic versus primary: Genomic analysis suggests a metastatic origin for breast cancer previously diagnosed as metachronous vulvar ectopic breast cancer

    by Sabina Swierczek, Deep Pandya, Jean-Noel Billaud, Boris Reva, Magdalena Swierczek, Matthew Reeves, Sara Farisello, Steven Sieber, Anya Laibangyang, Vaagn Andikyan, et al.

    Introduction: Accessory breast tissue is a rare finding in the general population with an incidence of 1-2%. Ectopic mammary tissue may occur anywhere along the milk line, from the axilla to the groin. Thus, breast cancer present in the vulva may arise as a primary breast adenocarcinoma or distant metastasis. Differentiating the two can be clinically challenging but is critically important as it impacts prognosis and treatment. Using genomic and bioinformatic approaches, we re-evaluated a previously histopathologically diagnosed rare case of metachronous vulvar ectopic breast cancer. Methods: Two biobanked breast tumor samples were obtained from a 43-year-old woman diagnosed with in situ breast cancer 17 months prior to her presentation and diagnosis with vulvar ectopic breast carcinoma. Whole exome (WES) and whole transcriptomic sequencing (RNAseq) were performed on all breast and vulvar tumor samples. Bioinformatics analysis was performed using the QIAGEN software suite (CLC Genomic Workbench, QCI-T) and Ingenuity Pathway Analysis (IPA). Sequence variants with >10 reads and 5% AF were selected for analysis. Results: We performed detailed molecular characterization of breast and vulvar tumor samples. WES profiles revealed, respectively, 4904 and 166 somatic mutations from primary breast and vulva tumor tissues. Among these mutations, 60 mutations were shared between primary breast and vulva tumors. Given the length of the WES target (~54MB). We calculated the probability that the shared mutations could occur by chance alone. To estimate this likelihood, we made the assumption that all positions interrogated by WES could be mutated with equal probability. Under this assumption, it is highly unlikely that the 60 identical mutations identified in multiple samples would occur by chance alone (Fisher exact test - p 100) Beyond these shared mutations, we identified a number of known breast cancer functional variants including variants in TP53, KMT2D, MET and an additional 32 likely pathogenic genes in the vulvar tumor that were not shared with the patient’s original breast tumor tissues. Similarly, we also identified a pathogenic variant in PRKAR1A and an additional 95 likely pathogenic variants in genes including ATRX, ATXN3, CTBP2, SCN2A only in the breast tumor. Conclusion: This illustrative case provides an interesting resolution to a clinically difficult question: differentiating synchronous or metachronous breast carcinoma in the vulva. While unusual, answering this question correctly significantly impacts staging and treatment for that patient. Citation Format: Sabina Swierczek, Deep Pandya, Jean-Noel Billaud, Boris Reva, Magdalena Swierczek, Matthew Reeves, Sara Farisello, Steven Sieber, Anya Laibangyang, Vaagn Andikyan, John A. Martignetti, Linus Chuang. Metastatic versus primary: Genomic analysis suggests a metastatic origin for breast cancer previously diagnosed as metachronous vulvar ectopic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 70.

  • Open Access

    Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer

    by Dimple Chakravarty, Parita Ratnani, Li Huang, Zachary Dovey, Stanislaw Sobotka, Roy Berryhill, Harri Merisaari, Majd Al Shaarani, Richa Rai, Ivan Jambor, et al.

    The impact of pelvic inflammation on prostate cancer (PCa) biology and aggressive phenotype has never been studied. Our study objective was to evaluate the role of pelvic inflammation on PCa aggressiveness and its association with clinical outcomes in patients following radical prostatectomy (RP). This study has been conducted on a retrospective single-institutional consecutive cohort of 2278 patients who underwent robot-assisted laparoscopic prostatectomy (RALP) between 01/2013 and 10/2019. Data from 2085 patients were analyzed to study the association between pelvic inflammation and adverse pathology (AP), defined as Gleason Grade Group (GGG) > 2 and ≥ pT3 stage, at resection. In a subset of 1997 patients, the association between pelvic inflammation and biochemical recurrence (BCR) was studied. Alteration in tumor transcriptome and inflammatory markers in patients with and without pelvic inflammation were studied using microarray analysis, immunohistochemistry, and culture supernatants derived from inflamed sites used in functional assays. Changes in blood inflammatory markers in the study cohort were analyzed by O-link. In univariate analyses, pelvic inflammation emerged as a significant predictor of AP. Multivariate cox proportional-hazards regression analyses showed that high pelvic inflammation with pT3 stage and positive surgical margins significantly affected the time to BCR (p ≤ 0.05). PCa patients with high inflammation had elevated levels of pro-inflammatory cytokines in their tissues and in blood. Genes involved in epithelial-to-mesenchymal transition (EMT) and DNA damage response were upregulated in patients with pelvic inflammation. Attenuation of STAT and IL-6 signaling decreased tumor driving properties of conditioned medium from inflamed sites. Pelvic inflammation exacerbates the progression of prostate cancer and drives an aggressive phenotype.


  • Open Access

    CPTAC Pancancer Phosphoproteomics Kinase Enrichment Analysis with ProKAP Provides Insights into Immunogenic Signaling Pathways

    by Anna Calinawan, Weiping Ma, John Erol Evangelista, Boris Reva, Francesca Petralia, Avi Ma’ayan, Pei Wang

    The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) initiative has generated extensive phosphoproteomics and proteomics data for tumor and tumor-adjacent normal tissue across multiple cancer types. This dataset provides an unprecedented opportunity to systematically characterize pan-cancer kinase activities, which is essential for coupling tumor subtypes with kinase inhibitors as potential treatment. In this work, we performed Kinase Enrichment Analysis (KEA) using a CPTAC phosphoproteomics dataset to identify putative differences in kinase state between tumor and normal tissues within and across five types of cancer. We then implemented an interactive web-portal, the ProTrack Kinase Activity Portal (ProKAP), for querying, visualizing, and downloading the derived pan-cancer kinase activity scores together with the corresponding sample metadata, and protein and phosphoprotein expression profiles. To illustrate the usage of this digital resource, we analyzed the association between kinase activity scores and immune subtypes of clear cell renal cell carcinoma (ccRCC) derived from the CPTAC ccRCC study. We found multiple kinases, whose inhibition has been suggested to have therapeutic effect in other tumor types, are highly active in CD8+-enriched ccRCC tumors. The ProTrack Kinase Activity Portal (ProKAP) is available at: https://pancan-kea3.cptac-data-view.org .

  • Immune Escape in Prostate Cancer

    by Boris A. Reva, Tatiana Omelchenko, Sujit S. Nair, Ashutosh K. Tewari


  • Open Access

    Prioritization of prostate cancer to immune checkpoint therapy by ranking tumors along IFN-γ axis and identification of immune resistance mechanisms

    by Boris Reva, Tatiana Omelchenko, Anna Calinawan, Sujit Nair, Eric Schadt, Ash Tewari

    We propose priotirization of prostate cancer patients to PD-L1 checkpoint therapy by assessing activity of IFN-γ/PD-L1 signaling in tumor from transcriptional profile. To this end, we introduced a new approach for inferring pathway activity and suppression (IPAS) by assessing significance of positioning pathway’s genes expression levels at top (activation) or bottom (suppression) in gene expression profile of a given tumor. By ordering tumors along IFN-γ/PD-L1 axis, we determined distinct “IFN-γ-depleted” and “IFN-γ-enriched” immune subtypes, genes involved in immune evasion and potential targets for combination therapy. Using IPAS scoring method, we proposed biomarker panels for accurate ranking tumors along IFN-γ/PD-L1 axis.


  • Open Access

    Post-Anticoagulant D-dimer as a Highly Prognostic Biomarker of COVID-19 Mortality

    by Xiaoyu Song, Jiayi Ji, Boris Reva, Himanshu Joshi, Anna Pamela Calinawan, Madhu Mazumdar, Emanuela Taioli, Pei Wang, Rajwanth Veluswamy

    Importance: Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe COVID-19 illness. Objective: To determine whether D-dimer levels after anticoagulation treatment is predictive of in-hospital mortality. Design: Retrospective study using electronic health record data. Setting: A large New York City hospital network serving a diverse, urban patient population. Participants: Adult patients hospitalized for severe COVID-19 infection who received therapeutic anticoagulation for thromboprophylaxis between February 25, 2020 and May 31, 2020. Exposures: Mean and trend of D-dimer levels in the 3 days following the first therapeutic dose of anticoagulation. Main Outcomes: In-hospital mortality versus discharge. Results: 1835 adult patients (median age, 67 years [interquartile range, 57-78]; 58% male) with PCR-confirmed COVID-19 who received therapeutic anticoagulation during hospitalization were included. 74% (1365) of patients were discharged and 26% (430) died in hospital. The study cohort was divided into four groups based on the mean D-dimer levels and its trend following anticoagulation initiation, with significantly different in-hospital mortality rates (p<0.001): 49% for the high mean-increase trend (HI) group; 27% for the high-decrease (HD) group; 21% for the low-increase (LI) group; and 9% for the low-decrease (LD) group. Using penalized logistic regression models to simultaneously analyze 67 variables (baseline demographics, comorbidities, vital signs, laboratory values, D-dimer levels), post-anticoagulant D-dimer groups had the highest adjusted odds ratios (ORadj) for predicting in-hospital mortality. The ORadj of in-hospital death among patients from the HI group was 6.58 folds (95% CI 3.81-11.16) higher compared to the LD group. The LI (ORadj: 4.06, 95% CI 2.23-7.38) and HD (ORadj: 2.37; 95% CI 1.37-4.09) groups were also associated with higher mortality compared to the LD group. Conclusions and Relevance: D-dimer levels and its trend following the initiation of anticoagulation have high and independent predictive value for in-hospital mortality. This novel prognostic biomarker should be incorporated into management protocols to guide resource allocation and prospective studies for emerging treatments in hospitalized COVID-19 patients. Key Points: Question: Are D-dimer levels following therapeutic anticoagulation predictive of mortality in hospitalized COVID-19 patients? Finding: In a retrospective study of 1835 adult COVID-19 patients who received therapeutic anticoagulation for thromboprophylaxis during hospitalization, 1365 (74%) patients were discharged and 470 (26%) died. Post-anticoagulant D-dimer levels and trends were significantly and independently predictive of mortality. Meaning: Active monitoring of post-anticoagulant D-dimer levels in hospitalized COVID-19 patients is a novel strategy for stratifying individual risk of in-hospital mortality that can help guide resource allocation and prospective studies for emerging treatments for severe COVID-19 illness.


  • ProTrack: An Interactive Multi‐Omics Data Browser for Proteogenomic Studies

    by Anna Pamela Calinawan, Xiaoyu Song, Jiayi Ji, Saravana Mohan Dhanasekaran, Francesca Petralia, Pei Wang, Boris Reva

    The Clinical Proteomic Tumor Analysis Consortium (CPTAC) initiative has generated extensive multi‐omics data resources of deep proteogenomic profiles for multiple cancer types. To enable the broader community of biological and medical researchers to intuitively query, explore, and download data and analysis results from various CPTAC projects, a prototype user‐friendly web application called “ProTrack” is built with the CPTAC clear cell renal cell carcinoma (ccRCC) data set ( http://ccrcc.cptac-data-view.org ). Here the salient features of this application which provides a dynamic, comprehensive, and granular visualization of the rich proteogenomic data is described.


  • Open Access

    ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies

    by Anna Pamela Calinawan, Xiaoyu Song, Jiayi Ji, Saravana Mohan Dhanasekaran, Francesca Petralia, Pei Wang, Boris Reva

    The Clinical Proteomic Tumor Analysis Consortium (CPTAC) initiative has generated extensive multi-omics data resources of deep proteogenomic profiles for multiple cancer types. To enable the broader community of biological and medical researchers to intuitively query, explore, and download data and analysis results from various CPTAC projects, we built a prototype user-friendly web application called “ProTrack” with the CPTAC clear cell renal cell carcinoma (ccRCC) data set (http://ccrcc.cptac-data-view.org). Here we describe the salient features of this application which provides a dynamic, comprehensive, and granular visualization of the rich proteogenomic data.Statement of Significance: The CPTAC initiative (https://proteomics.cancer.gov/) has generated multi-omics data for multiple cancer types to understand the proteogenomic aberrations of these malignancies. Collectively this effort has so far produced a large data resource for the research community, including high-throughput profiles for proteome, phosphoproteome, whole exome, whole genome, transcriptome, and DNA methylome. To make this valuable data-resource useful to the larger research community, there is a pressing need for development of user-friendly, readily accessible, and easily shared analytic and visualization tools for aligning multi-omics data and exploring alterations in key cancer genes, to drive and support new biological hypotheses. To bridge this gap, we have developed CPTAC ProTrack, an interactive web application which uses a multilayered, client-server architecture in order to deliver an interactive web experience to any user of a modern web-browser. This tool is intentionally designed accessible for researchers, biologists, and clinicians who are interested in multi-omic data without any need to code.


  • A02 Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

    by M.A. Gillette, S. Satpathy, S. Cao, S. Dhanasekaran, S. Vasaikar, K. Krug, F. Petralia, Y. Li, W.-W. Liang, B. Reva, et al.


  • Open Access

    A new molecular signature method for prediction of driver cancer pathways from transcriptional data

    by Dmitry Rykunov, Noam D. Beckmann, Hui Li, Andrew Uzilov, Eric E. Schadt, Boris Reva

    Assigning cancer patients to the most effective treatments requires an understanding of the molecular basis of their disease. While DNA-based molecular profiling approaches have flourished over the past several years to transform our understanding of driver pathways across a broad range of tumors, a systematic characterization of key driver pathways based on RNA data has not been undertaken. Here we introduce a new approach for predicting the status of driver cancer pathways based on signature functions derived from RNA sequencing data. To identify the driver cancer pathways of interest, we mined DNA variant data from TCGA and nominated driver alterations in seven major cancer pathways in breast, ovarian and colon cancer tumors. The activation status of these driver pathways were then characterized using RNA sequencing data by constructing classification signature functions in training datasets and then testing the accuracy of the signatures in test datasets. The signature functions differentiate well tumors with nominated pathway activation from tumors with no signs of activation: average AUC equals to 0.83. Our results confirm that driver genomic alterations are distinctively displayed at the transcriptional level and that the transcriptional signatures can generally provide an alternative to DNA sequencing methods in detecting specific driver pathways.